Tilray Brands, Inc. announced a groundbreaking achievement in the medical cannabis industry in Portugal. Following the successful approval of Tilray whole flower THC 18, Tilray Medical has now received approval for the first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20, in Portugal, marking a significant milestone in medical cannabis availability and patient care within the country. This landmark approval, confirmed on March 11, 2024, underscores Tilray's commitment to expanding safe and regulated access to medical cannabis for patients in need.

The newly approved medical cannabis extract is set to launch in late spring, offering new therapeutic options for patients across Portugal with specified medical conditions. The approved extract is indicated for use in several critical areas of patient care. Tilray Medical continues to be a global leader in the medical cannabis industry, offering a diverse portfolio of EU-GMP certified medicinal cannabis products.

With operations extending over 20 countries, Tilray Medical is dedicated to supporting medical cannabis patient care worldwide through quality products accessible via healthcare practitioners.